India's medical regulatory system is moving into the next phase of a high-profile ethics case involving doctors who allegedly accepted pharma-sponsored overseas travel benefits valued at nearly ₹1.9 crore. According to recent reports, the National Medical Commission (NMC) received the names of 27 doctors from the Department of Pharmaceuticals (DoP) in September 2025, despite an earlier investigation finding 30 doctors responsible for accepting the benefits. The NMC subsequently forwarded the names to nine State Medical Councils for inquiry and further action.
The case stems from a complaint alleging that a pharmaceutical company funded travel and accommodation for doctors attending international meetings held in Monaco and Paris in 2024. The trips were reportedly linked to conferences focused on aesthetic and anti-aging medicine. Investigators found that the total expenditure on flights…
